Symbols

GRCL(Delisted)

Gracell·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GRCL

Gracell Biotechnologies Inc.

A Chinese clinical-stage biopharmaceutical company that develops cell therapies for the treatment of cancer

Industry

Established Date

05/22/2018

Listing Date

01/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

314

Fiscal Year Ends

12-31

Website

www.gracellbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Building 12, Block B, Phase II, Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park, 215123, People’s Republic of China

Business

Development of cell-based therapies for cancer

Introduction

Genxi Biotechnology, an exempted limited liability company incorporated in the Cayman Islands on May 22, 2018, is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Genxi Bio is developing a rich pipeline of autologous and allogeneic clinical-stage cancer treatment products. These products are expected to overcome the persistent major industry challenges of traditional CAR-T therapies, including long production time, poor product cell quality, high treatment cost and lack of effective treatment for solid tumors.

Company Financials

EPS

GRCL has released its 2023 Q3 earnings. EPS was reported at -0.1, versus the expected -0.2, beating expectations. The chart below visualizes how GRCL has performed over recent quarters, highlighting trends in earnings surprises.